DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635 (c) (4).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...

The notification letter has no immediate effect on the listing of the Company’s class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD”.

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT ™ (cosibelimab-ipdl). UNLOXCYT is the first and ...

About GlohCo GlohCo is a healthtech intelligence platform focused on building software and data-driven tools for use across digital health and care delivery environments.

NORTH PALM BEACH, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced that it has invested in the common stock of Opendoor ...

QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health infrastructure company supporting primary care practices, today announced that it has initiated a formal process to expand its board of ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am ...

In 2025, Baylor Genetics was named an official genetic testing partner of the Child Neurology Society.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance ...